Psychoactive drugs influence brain-derived neurotrophic factor and neurotrophin 4/5 levels in the serum of colorectal cancer patients.

Biomed Rep

Department of Digestive, General and Endocrinal Surgery, University of Limoges Teaching Hospital, F-87042 Limoges Cedex, France; Laboratory EA 3842, Cellular Homeostasis and Pathologies, Medicine and Pharmacy Faculties, University of Limoges, F-87025 Limoges Cedex, France; CNRS 3503 Department, Federative Research Institute, Genomic, Environment, Immunity, Health and Therapeutics, University of Limoges, F-87025 Limoges Cedex, France.

Published: January 2017

AI Article Synopsis

  • Previous research has linked brain-derived neurotrophic factor (BDNF) with tumor growth in various cancers, but its specific effects in colorectal cancer (CRC) were not thoroughly examined until this study.
  • The study measured serum levels of BDNF and neurotrophic factor 4 (NT4/5) in CRC patients and found NT4 correlated with psychoactive drug intake, while BDNF was specifically linked to benzodiazepine use.
  • Although neither BDNF nor NT4/5 can serve as reliable prognostic or diagnostic markers for CRC, higher levels of these factors were associated with improved survival, suggesting their potential role in monitoring depression and predicting outcomes in CRC patients.

Article Abstract

Previous studies have reported the association between brain-derived neurotrophic factor (BDNF) and tumor development in numerous cancers. However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients. The present study investigated the significance of serum BDNF and the NT4/5 in association with the intake of psychoactive drugs in CRC patients. Soluble BDNF and NT4 in the serum were assessed by ELISA. Although no correlation of BDNF and NT4 with the CRC stage was identified, a positive correlation was found between NT4 and the intake of psychoactive drugs (P=0.0457). For BDNF, a correlation was found in particular with the intake of benzodiazepine (P=0.0221). As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients. However, high expression of BDNF and NT4 was significantly associated with better survival. Therefore, these NTs may be used as markers for monitoring depression or predicting survival in CRC patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244794PMC
http://dx.doi.org/10.3892/br.2016.801DOI Listing

Publication Analysis

Top Keywords

crc patients
16
psychoactive drugs
12
neurotrophic factor
12
bdnf nt4
12
brain-derived neurotrophic
8
colorectal cancer
8
cancer patients
8
bdnf
8
bdnf nt4/5
8
intake psychoactive
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!